NCT00113256 2024-08-02
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Astex Pharmaceuticals, Inc.
Phase 2/3 Terminated
Clinical Trials
7 trialsNCT00005869 2013-12-04
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005870 2013-12-04
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005871 2013-12-04
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005874 2013-12-04
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005876 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005877 2013-12-04
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown